Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial.

ABSTRACT:

Background

REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) led to new guidelines for statin use among people with HIV (PWH) with low to moderate risk for atherosclerotic cardiovascular disease (ASCVD). Little is known about the natural history of diabetes mellitus (DM) or mechanisms contributing to statin effects on DM among this population.

Objective

To determine the contribution of known DM risk factors to excess risk for DM with pitavastatin in REPRIEVE.

Design

Phase 3, primary ASCVD prevention trial over a median of 5.6 years of follow-up. (ClinicalTrials.gov: NCT02344290).

Setting

Global, multicenter trial.

Participants

7731 PWH aged 40 to 75 years with low to moderate ASCVD risk (by the pooled cohort equations from the American Colleg

SUBMITTER: Fitch KV 

PROVIDER: S-EPMC11573625 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature